The first Trump administration set a goal to end the HIV epidemic by 2030. The second Trump administration wants to burn it ...

The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

Electronic cigarettes use may pose lower cardiovascular risks in people living with HIV compared to tobacco cigarette use, ...

Electronic cigarette use may pose lower cardiovascular risks in people living with HIV compared to tobacco cigarette use, new ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

About the Phase 3 data from MK-8591A-052 MK-8591A-052 ... once-daily DOR/ISL (100mg/0.25mg) in adults with HIV-1 infection that has been virologically suppressed on BIC/FTC/TAF (50mg/200mg/25mg).

Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...

Merck & Co (MSD) is looking to file for approval of its human immunodeficiency virus (HIV) treatment after two positive Phase III trial readouts. Its once-daily oral combination of the approved ...